Eribulin - CAS 253128-41-5
Catalog number: B0084-305436
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C40H59NO11
Molecular Weight:
729.9
COA:
Inquire
Targets:
Microtubule/Tubulin
Description:
Eribulin suppressed centromere dynamics at concentrations that arrest mitosis. At 60 nmol/L eribulin (2 x mitotic IC(50)), the relaxation rate was suppressed 21%, the time spent paused increased 67%, and dynamicity decreased 35% (but without reduction in mean centromere separation), indicating that eribulin decreased normal microtubule-dependent spindle tension at the kinetochores, preventing the signal for mitotic checkpoint passage. [(3)H]eribulin binds soluble tubulin at a single site; however, this binding is complex with an overall K(d) of 46 microM, but also showing a real or apparent very high affinity (K(d) = 0.4 microM) for a subset of 25% of the tubulin. Eribulin also binds microtubules with a maximum stoichiometry of 14.7 +/- 1.3 molecules per microtubule (K(d) = 3.5 microM), strongly suggesting the presence of a relatively high-affinity binding site at microtubule ends. At 100 nM, the concentration that inhibits microtubule plus end growth by 50%, we found that one molecule of eribulin is bound per two microtubules, indicating that the binding of a single eribulin molecule at a microtubule end can potently inhibit its growth. Eribulin does not suppress dynamic instability at microtubule minus ends. Eribulin's in vivo superiority derives from its ability to induce irreversible mitotic blockade, which appears related to persistent drug retention and sustained Bcl-2 phosphorylation.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-305436 1 mg $998 In stock
Bulk Inquiry
Purity:
>98%
Synonyms:
Halaven; B1939; E7389; ER-086526
MSDS:
Inquire
InChIKey:
UFNVPOGXISZXJD-JBQZKEIOSA-N
InChI:
InChI=1S/C40H59NO11/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41/h19,23-39,43H,2-3,5-18,41H2,1,4H3/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+/m1/s1
Canonical SMILES:
CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O
1.Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Aftimos P1, Polastro L2, Ameye L3, Jungels C2, Vakili J2, Paesmans M3, van den Eerenbeemt J2, Buttice A2, Gombos A2, de Valeriola D2, Gil T2, Piccart-Gebhart M2, Awada A2. Eur J Cancer. 2016 Apr 20;60:117-124. doi: 10.1016/j.ejca.2016.03.010. [Epub ahead of print]
BACKGROUND: Eribulin is a non-taxane microtubule dynamics inhibitor that showed a survival benefit versus treatment of physician's choice in a phase III trial enrolling patients with metastatic breast cancer (MBC).
2.In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab.
Ueda S1, Saeki T1, Takeuchi H1, Shigekawa T1, Yamane T2, Kuji I2, Osaki A1. Br J Cancer. 2016 May 3. doi: 10.1038/bjc.2016.122. [Epub ahead of print]
BACKGROUND: Eribulin mesylate (eribulin) is a first-in-class halichondrin B-based microtubule dynamics inhibitor. To compare the anti-angiogenic activity of eribulin to that of bevacizumab, we compared tumour vessel remodelling and reoxygenation between the two agents.
3.Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide.
Ro J1, Cheng FT2, Sriuranpong V3, Villalon A4, Smruti BK5, Tsang J6, Yap YS7; Asian Working Group for Eribulin Clinical Guide. J Breast Cancer. 2016 Mar;19(1):8-17. doi: 10.4048/jbc.2016.19.1.8. Epub 2016 Mar 25.
Eribulin, an antimicrotubule chemotherapeutic agent, is approved for the treatment of pretreated metastatic breast cancer (mBC) based on the positive outcomes of phase II and phase III clinical trials, which enrolled mainly Western patients. Eribulin has recently been approved in an increasing number of Asian countries; however, there is limited clinical experience in using the drug in certain countries. Therefore, we established an Asian working group to provide practical guidance for eribulin use based on our clinical experience. This paper summarizes the key clinical trials, and the management recommendations for the reported adverse events (AEs) of eribulin in mBC treatment, with an emphasis on those that are relevant to Asian patients, followed by further elaboration of our eribulin clinical experience. It is anticipated that this clinical practice guide will improve the management of AEs resulting from eribulin treatment, which will ensure that patients receive the maximum treatment benefit.
4.Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
Kawano S1, Asano M1, Adachi Y1, Matsui J2. Anticancer Res. 2016 Apr;36(4):1553-61.
BACKGROUND: Eribulin mesilate (eribulin), a first-in-class halichondrin B-based microtubule dynamics inhibitor, has been shown to promote vascular remodeling and reversal of epithelial-mesenchymal transition (EMT) apart from its antimitotic activity in breast cancer models.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Microtubule/Tubulin Products


CAS 152044-54-7 Epothilone B

Epothilone B
(CAS: 152044-54-7)

Epothilone B, also called Patupilone, is a microtubule stabilization agent (EC0.01= 1.8 μM). It induces mitotic arrest at the G2-M transition in Hs578T (IC50 = ...

CAS 849550-05-6 Cevipabulin

Cevipabulin
(CAS: 849550-05-6)

Cevipabulin, is a small synthetic molecule of triazolopyrimidine derivative with potential antitumor activity. With a novel mechanism of action distinct from th...

CAS 64-86-8 Colchicine

Colchicine
(CAS: 64-86-8)

Colchicine, a toxic plant-derived alkaloid extracted from plants of the genus Colchicum, inhibits microtubule polymerization (IC50 = 3.2 μM).

CAS 162652-95-1 Vinflunine

Vinflunine
(CAS: 162652-95-1)

Vinflunine is a new vinca alkaloid uniquely fluorinated with the properties of mitotic-arresting and tubulin-interacting activity.

CAS 204205-90-3 Indibulin

Indibulin
(CAS: 204205-90-3)

Indibulin, also called D 24851, estabilizes tubulin polymerization (IC50 = 0.3 μM) and induces tumor cell cycle arrest and apoptosis. In vitro: blocking cell cy...

CAS 183133-96-2 Cabazitaxel

Cabazitaxel
(CAS: 183133-96-2)

Cabazitaxel increases CYP3A enzyme activities in rat hepatocytes. The mean ex-vivo human plasma protein binding of Cabazitaxel is 91.6%.

CAS 71486-22-1 Vinorelbine

Vinorelbine
(CAS: 71486-22-1)

Vinorelbine, also called Navelbine, a 5′NOR semisynthetic vinca alkaloid which arrests tumor cell growth in metaphase by binding to tubulin and preventing form...

CAS 108852-90-0 Nemorubicin

Nemorubicin
(CAS: 108852-90-0)

Nemorubicin, currently being developed by Nerviano, is a doxorubicin derivative that differs significantly from its parent drug in terms of spectrum of antitumo...

CAS 1201898-17-0 Vinflunine Tartrate

Vinflunine Tartrate
(CAS: 1201898-17-0)

Vinflunine induces apoptosis in neuroblastoma SK-N-SH cells through a postmitotic G1 arrest and a mitochondrial pathway in a concentration-dependent manner with...

CAS 168555-66-6 Fosbretabulin disodium

Fosbretabulin disodium
(CAS: 168555-66-6)

Fosbretabulin disodium is the disodium salt of a water-soluble phosphate derivative of a natural stilbenoid phenol derived from the African bush willow (Combret...

CAS 114977-28-5 Docetaxel

Docetaxel
(CAS: 114977-28-5)

Docetaxel, also called Taxoltere metro, a semisynthetic side-chain analogue of taxol differing at two positions in its chemical structure, is an inhibitior of m...

CAS 68786-66-3 Triclabendazole

Triclabendazole
(CAS: 68786-66-3)

Triclabendazole is a benzimidazole, it binds to tubulin impairing intracellular transport mechanisms and interferes with protein synthesis.

ACI-35

ACI-35 is a liposome-based vaccine designed to stimulate a patient’s immune system to produce antibodies against the misfolded and phosphorylated pathogenic for...

CAS 194468-36-5 Vinflunine ditartrate

Vinflunine ditartrate
(CAS: 194468-36-5)

Vinflunine, a semisynthetic derivative of Vinorelbine, is the first fluorinated microtubule inhibitor belonging to the Vinca alkaloids family endowed with uniqu...

CAS 154554-41-3 CHM 1

CHM 1
(CAS: 154554-41-3)

CHM 1 is an apoptosis inducer with potent antitumor activity in human hepatocellular carcinoma. It inhibits tubulin polymerization in vitro and in vivo, and res...

Dolastatin 10 trifluoroacetate

Dolastatin 10 trifluoroacetate inhibits tubulin polymerization and induces tubulin aggregation in vitro.

CAS 945771-74-4 BNC-105

BNC-105
(CAS: 945771-74-4)

BNC105 is a novel compound being developed by Bionomics as a Vascular Disrupting Agent (VDA) for treatment of cancer. VDAs are drugs that disrupt the blood vess...

AADvac-1

AADvac-1 is an active vaccine designed to raise antibodies against pathological tau protein (the primary constituent of neurofibrillary pathology in AD). These ...

CAS 52205-73-9 Estramustine phosphate sodium

Estramustine phosphate sodium
(CAS: 52205-73-9)

Estramustine phosphate sodium is an antimicrotubule chemotherapy agent. It arrests prostate cancer cells in the G2/M phase of the cell cycle.

CAS 74588-78-6 D-64131

D-64131
(CAS: 74588-78-6)

D-64131, under the IUPAC name (5-methoxy-1H-indol-2-yl)-phenylmethanone, is a 2-aroylindole derivatives that inhibits tubulin polymerization. In vitro: Inhibits...

Chemical Structure

CAS 253128-41-5 Eribulin

Quick Inquiry

Verification code

Featured Items